GlassScriptPhysician profile
Robin A Horn
NPI 1609842608
$9,549.81
in general payments reported to CMS, 2019-2025
30 companies · $1,119 in 2025
The $1,119 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,983 · 2020: $4,923 · 2021: $356 · 2022: $194 · 2023: $415 · 2024: $561 · 2025: $1,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,082 · Education: $12.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,082.13 |
| Education | $12.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lantheus Medical Imaging, INC. | $5,625.81 | 2019-2025 | Definity |
| Janssen Pharmaceuticals, INC | $486.86 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $468.78 | 2020-2025 | Jardiance |
| Pfizer INC. | $401.93 | 2019-2025 | |
| Amgen INC. | $321.40 | 2019-2025 | Repatha |
| Novartis Pharmaceuticals Corporation | $313.77 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $305.31 | 2019-2024 | Brilinta |
| Aop Health US, LLC | $236.83 | 2025 | Rapiblyk |
| E.R. Squibb & Sons, L.L.C. | $233.95 | 2019-2025 | Eliquis, Camzyos |
| Heartflow, INC. | $186.98 | 2022-2025 | Ffrct |
| Alnylam Pharmaceuticals INC. | $119.50 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $119.29 | 2019-2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $92.35 | 2019-2022 | |
| Philips North America LLC | $85.81 | 2023-2025 | Mcot |
| Bayer Healthcare Pharmaceuticals INC. | $57.17 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $55.85 | 2025 | Triclip |
| Regeneron Healthcare Solutions, INC. | $55.54 | 2019-2025 | Evkeeza |
| Merck Sharp & Dohme LLC | $54.25 | 2021-2023 | Verquvo |
| Kowa Pharmaceuticals America, INC. | $42.23 | 2019-2021 | |
| Boston Scientific Corporation | $35.90 | 2019 | |
| Preventice Services, LLC | $35.62 | 2019 | |
| Siemens Medical Solutions USA, INC. | $33.34 | 2019 | |
| Medtronic, INC. | $31.28 | 2025 | Aurora Ev-Icd Mri Surescan |
| Bardy Diagnostics, INC. | $30.02 | 2019 | |
| Genzyme Corporation | $27.55 | 2024 | |
| Abiomed | $25.34 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $18.53 | 2024 | Arcalyst |
| Ionis Pharmaceuticals, INC. | $18.30 | 2025 | Tryngolza |
| Bridgebio Pharma, INC. | $16.23 | 2025 | Attruby |
| Amarin Pharma, INC. | $14.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Horn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.